<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527137</url>
  </required_header>
  <id_info>
    <org_study_id>20000100</org_study_id>
    <nct_id>NCT00527137</nct_id>
  </id_info>
  <brief_title>NESP Pediatric Study</brief_title>
  <official_title>An Open-label, Randomized, Non-inferiority Study of Novel Erythropoiesis Stimulating Protein (NESP) and Recombinant Human Erythropoietin (rHuEPO) for the Treatment of Anemia in Pediatric Subjects With Chronic Renal Insufficiency (CRI) or End-stage Renal Disease (ESRD) Receiving Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      Open-label, randomized study of NESP in pediatric subjects 18 years of age or younger.
      Subjects will receive study drug (NESP or rHuEPO) for 28 weeks after a 2 week screening and
      baseline period. During the study, procedures include bloodwork for laboratory assessments
      and vital signs. Dose titration determined by hemoglobin values taken weekly during the
      study. Antibody samples taken at baseline and during the end of study assessments. A physical
      examination and laboratory tests will conclude the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate that NESP is comparable (not inferior) to rHuEPO for the treatment of anemia in pediatric subjects with CRI or ESRD receiving dialysis</measure>
    <time_frame>Entire Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of NESP in the treatment of anemia in the pediatric population with CRI or ESRD</measure>
    <time_frame>Entire Study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pre-dialysis</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>rHuEPO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>darbepoetin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darbepoetin alfa</intervention_name>
    <description>Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL</description>
    <arm_group_label>darbepoetin alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuEPO</intervention_name>
    <description>same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL</description>
    <arm_group_label>rHuEPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1 to 18 years of age

          -  ESRD receiving dialysis or CRI with eGFR less than 30 mL/min

          -  Baseline hemoglobin 9.5 - 12.5 g/dL and iron replete

          -  Stable rHuEPO therapy for 8 weeks

        Exclusion Criteria:

          -  Scheduled for a living-related kidney transplant

          -  Uncontrolled blood pressure

          -  seizure activity

          -  Hyperparathyroidism

          -  Major surgery within 12 weeks or active inflammatory disease

          -  Currently receiving antibiotics

          -  Clinical evidence of malignancy

          -  Pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.aranesp.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Warady BA, Arar MY, Lerner G, Nakanishi AM, Stehman-Breen C. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2006 Aug;21(8):1144-52. Epub 2006 May 25.</citation>
    <PMID>16724235</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2007</study_first_submitted>
  <study_first_submitted_qc>September 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>May 6, 2013</last_update_submitted>
  <last_update_submitted_qc>May 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

